AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Boston Scientific Corporation
Video analysis: BSX
All videosNo video analysis for this stock yet. Request one from our team.
News: BSX
Boston Scientific Leans on Acquisitions to Drive Long-Term Growth
BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.
Boston Scientific: $43 Finally Prices In A Bad 2026
Boston Scientific's cyberattack will hurt third-quarter results, but manufacturing and shipping recovered quickly enough that much of the missing revenue should be delayed rather than lost. I am more concerned about WATCHMAN and U.S. electrophysiology, which had already slowed before the attack, and the additional debt coming with Penumbra. BSX shares now trade near 13 times the company's withdrawn earnings forecast. I estimate fair value at $55, leaving enough room for a Buy without assuming that growth immediately returns.
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Boston Scientific (BSX) reached $43.1 at the closing of the latest trading day, reflecting a -4.14% change compared to its last close.
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Boston Scientific Restores Key Operations After Cyberattack
The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the delivery of products.
Boston Scientific Corporation $BSX Shares Acquired by Concurrent Investment Advisors LLC
Concurrent Investment Advisors LLC boosted its holdings in Boston Scientific Corporation (NYSE: BSX) by 77.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 55,565 shares of the medical equipment provider's stock after purchasing an additional 24,166 shares during the quarter. Concurrent
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
Boston Scientific Corporation (NYSE:BSX) anticipates a material hit to its third-quarter and full-year 2026 financial results following an August cybersecurity incident that disrupted global operations.
